ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Director, IT Business Partner at Cogent Biosciences - ApplyBlast

Director, IT Business Partner

Cogent Biosciences

7 months ago

3.8 on Glassdoor

Waltham, Massachusetts, United States

Hybrid

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

A Director, IT Business Partner for Commercial, Medical Affairs and Corporate Applications at Cogent Biosciences supports the implementation and management of business systems, aligns with business leaders to execute technology roadmaps, and ensures compliance with regulatory and security standards.

Skills

Qualifications

Bachelor’s (or advanced) degree in Information Systems, Life Sciences or related fieldExperience working in biotech/pharmaceutical life science industry is preferred8+ years of hands-on technical leadership in commercial, medical affairs and corporate applications management8+ years of IT experience, with at least 5 years of Life Science industry experience5+ years of experience as an IT Business Partner supporting Commercial and Medical Affairs systems

About Cogent Biosciences

cogentbio.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2014

View Profile

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, including cancers, autoimmune conditions, and rare diseases. The company leverages validated biology to design best-in-class small molecule therapeutics, with its lead program bezuclastinib targeting conditions such as Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). Cogent operates discovery and development offices in Boulder, Colorado and Waltham, Massachusetts, and is actively advancing clinical-stage programs including a Phase 3 trial and an FDA-accepted NDA for bezuclastinib.